Form 4: Myriad Genetics CTO Departs, Sells Shares

Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, has departed the company and reported the disposition of shares related to tax withholdings from vested restricted stock units.

Summary

• Kevin Richard Haas, former Chief Technology Officer of Myriad Genetics, Inc. (MYGN), reported several dispositions of common stock.
• These dispositions, totaling 22,310 shares, occurred between March 13, 2026, and March 15, 2026, at a price of $4.66 per share.
• The shares were withheld by the Issuer to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs).
• Haas is no longer serving as CTO, effective March 16, 2026, and is therefore no longer subject to Section 16 reporting requirements.
• Following these transactions, Haas beneficially owns 180,022 shares of Myriad Genetics Common Stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development due to the departure of a key executive, the Chief Technology Officer, which can introduce uncertainty regarding the company's technological direction and innovation efforts.

Positives

• The vesting of restricted stock units indicates that performance milestones were met, which can be a positive sign for the company's operational achievements.

Negatives

• The departure of a Chief Technology Officer can create uncertainty regarding the company's future technological direction and innovation pipeline.

Risks

• Leadership transition risk: The departure of a key executive like the CTO can disrupt ongoing projects, strategic initiatives, and team morale, potentially impacting the company's ability to execute its technology roadmap.
• Loss of institutional knowledge: The company may experience a loss of critical expertise and historical context related to its technology development and intellectual property.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, beyond the implication of a leadership transition.

Industry Context

StockSavvy.ai notes that executive departures, particularly from key technology roles, are common in the fast-paced biotechnology and diagnostics industry. Such changes can sometimes signal strategic shifts or internal restructuring, which warrant close monitoring by investors. The sector often sees high executive mobility due to competitive talent markets and the dynamic nature of scientific innovation.

Comparison to Industry Standards

• Executive departures are a normal part of corporate lifecycle across industries, including biotechnology.
• The process of withholding shares for tax obligations upon RSU vesting is a standard practice for executive compensation in publicly traded companies, aligning with typical equity compensation structures seen at peers like Illumina or Exact Sciences.

Management Changes

Stakeholder Impact

• Shareholders: May experience uncertainty regarding future technological innovation and strategic direction due to the CTO's departure.
• Employees: The technology team may face leadership transition and potential shifts in project priorities.

Next Steps

• Myriad Genetics will likely need to announce a successor for the Chief Technology Officer role.
• Investors will monitor for any strategic shifts or operational impacts resulting from this leadership change.

Key Dates

Recommendation

The departure of a Chief Technology Officer is a significant event that introduces uncertainty. While the share dispositions are routine for tax purposes, the executive change warrants a cautious approach. Investors should hold their positions and await further clarity on succession planning and any potential strategic shifts before making new investment decisions.

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Executive Departure, CTO, Kevin Richard Haas, Restricted Stock Units, Tax Withholding, Corporate Governance, Biotechnology, Genetics